Document ID: chunk:federal_register_of_legislation:F2025C00119:clause:3_1:p35
Version: federal_register_of_legislation:F2025C00119
Segment Type: clause
Provision Reference: sch 3 cl 1 (pt 35/69)
Character Range: 436618–445385

be the sole PBS‑subsidised systemic anti‑cancer therapy for this condition.
                                                                                                                Patient must be undergoing treatment that does not occur beyond the following, whichever comes first: (i) the first instance of disease progression/recurrence, (ii) 12 months in total for this condition from the first administered dose; mark any remaining repeat prescriptions with the words 'cancelled' where (i)/(ii) has occurred.
C13443              P13443         Atezolizumab                                                                 Locally advanced or metastatic non‑small cell lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures ‑ Streamlined Authority Code 13443
                                                                                                                Initial treatment ‑ 3 weekly treatment regimen
                                                                                                                Patient must not have received prior treatment with a programmed cell death‑1 (PD‑1) inhibitor or a programmed cell death ligand‑1 (PD‑L1) inhibitor for non‑small cell lung cancer; AND
                                                                                                                Patient must have a WHO performance status of 0 or 1; AND
                                                                                                                The treatment must be the sole PBS‑subsidised systemic anti‑cancer therapy for this condition; AND
                                                                                                                The condition must have progressed on or after prior platinum based chemotherapy; OR
                                                                                                                The condition must have progressed after treatment with tepotinib.
C13445              P13445         Nivolumab                                                                    Locally advanced or metastatic non‑small cell lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures ‑ Streamlined Authority Code 13445
                                                                                                                Initial treatment as second‑line drug therapy
                                                                                                                Patient must not have received prior treatment with a programmed cell death‑1 (PD‑1) inhibitor or a programmed cell death ligand‑1 (PD‑L1) inhibitor for non‑small cell lung cancer; AND
                                                                                                                Patient must have a WHO performance status of 0 or 1; AND
                                                                                                                The treatment must be the sole PBS‑subsidised systemic anti‑cancer therapy for this condition; AND
                                                                                                                The condition must have progressed on or after prior platinum based chemotherapy; OR
                                                                                                                The condition must have progressed after treatment with tepotinib.
                                                                                                                The patient's body weight must be documented in the patient's medical records at the time treatment is initiated.
                                                                                                                Patients must only receive a maximum of 240 mg every two weeks or 480 mg every four weeks under a weight based or flat dosing regimen.
C13446              P13446         Atezolizumab                                                                 Locally advanced or metastatic non‑small cell lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures ‑ Streamlined Authority Code 13446
                                                                                                                Initial treatment ‑ 4 weekly treatment regimen
                                                                                                                Patient must not have received prior treatment with a programmed cell death‑1 (PD‑1) inhibitor or a programmed cell death ligand‑1 (PD‑L1) inhibitor for this condition; AND
                                                                                                                Patient must have a WHO performance status of 0 or 1; AND
                                                                                                                The treatment must be the sole PBS‑subsidised therapy for this condition; AND
                                                                                                                The condition must have progressed on or after prior platinum based chemotherapy; OR
                                                                                                                The condition must have progressed after treatment with tepotinib.
C13448              P13448         Atezolizumab                                                                 Stage IV (metastatic) non‑small cell lung cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures ‑ Streamlined Authority Code 13448
                                                                                                                Initial treatment 1
                                                                                                                Patient must be undergoing combination treatment with bevacizumab and platinum‑doublet chemotherapy.
                                                                                                                The condition must be non‑squamous type